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ABSTRACT

THE MORBIDITY & MORTALITY OF PREVALENT HEART FAILURE

By
Jennifer Kwon
Doctor of Public Health in Epidemiology
Loma Linda University School of Public Health, Loma Linda University, 2012
Synnove Knutsen, Chair

The first study population included 292 unselected consecutive patients from the
LLUMC heart failure clinic who were enrolled in the study from January to July 2006
and were followed up through the end of December 2010. The treatment policy at the
clinic was to uptitrate dosages of beta-adrenergic blockade (p-blockers), angiotensin
converting-enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) to the
most tolerable levels in order to reach target dosages, as recommended by the Heart
Failure Society of America (HFSA). Patients were classified into systolic heart failure
(ejection fraction (EF) <40%) or diastolic heart failure (EF>40%). All dosages of pblockers, ACEi and ARB were extracted through chart reviews and were used as the
main predictors of the patients' survival. Results from analyses showed that reaching
target dosages of p-blockers and ACEi/ARB may increase survival when compared to not
reaching target among the systolic HF population (HRp_biockers= 0-64, 95% Cl 0.26-1.56
and HRacei arb=0.50, 95% Cl 0.22-1.14). Similarly, the HR of 0.48 (95% Cl 0.13-1.81)
for p-blocker therapy and HR of 0.21 (95% Cl 0.04-1.07) for ACEi/ARB therapy
iii

suggests improvements in survival with these drug regiments among the diastolic HF
population. Unfortunately, the study lacked power to make the observations statistically
significant. A larger sample size is needed to adequately address the possible benefits of
these drugs for heart failure patients.
The second study is comprised of a random, representative sample of 200 cases of
self-reported congestive health failure (CHF) and 260 non-cases from the Adventist
Health Study-2 (AHS-2). A total of 67 cases and 147 non-cases were successfully
contacted or contacted through proxy and their consents were obtained for medical record
review. Consenting participants’ medical records were retrieved and examined for the
validity of self-reported heart failure. The sensitivity of self-reported CHF was calculated
as 97.4% and the specificity was 83.4%. The positive predictive value was 56.7% and the
negative predictive value was 99.3 %. Total agreement (accuracy) between presence of
self-reported heart failure and obtained physician-diagnosed heart failure from medical
records was 86.0%. Further study with a larger sample is necessary to obtain reliable
measures of validity of self-reported CHF in this population.
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CHAPTER 1
INTRODUCTION

The significance of heart failure in the realm of health care is substantial due to its
high prevalence and incidence. The subsequent excessive rates of heart failure-related
hospitalizations and its poor prognosis is a great public health concern. Continued
research is essential in order to find effective treatment for patients with heart failure and
more importantly, to work towards effective prevention.
Randomized clinical trials have shown that drug therapies at recommended
dosages significantly improve heart failure survival, but application of the recommended
dosages in clinical practice has not been extensively studied.
Large epidemiological studies are fundamental in investigating preventative
measures of heart failure. And with heart failure data collected from large cohorts, it is
important to estimate the validation of self-reported heart failure in order to ensure
reliability when using such self-reported health outcomes in analysis.
Aims
This dissertation has two main aims:
1. To analyze the association between drug therapies and the survival of an out-patient
population at the heart failure clinic in Loma Linda University Medical Center.
2. To validate self-reported, physician-diagnosed congestive heart failure among the
Adventist Health Study-2 population.
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CHAPTER 2
LITERATURE REVIEW

A. Pathology
Heart failure (HF) is a chronic condition where the body is unable to receive
adequate oxygen and nutrients because of the inadequate pumping of the heart due to
ventricular dysfunction. The American College of Cardiology/American Heart
Association (ACC/AHA) Task Force guidelines define chronic HF as a complex clinical
syndrome, a result of cardiac dysfunction that impairs the ability of the ventricle to fill
and eject blood.1 It is initiated by injury or stress on the myocardium, but it is a
progressive disease that manifests after multiple complications have further damaged or
weakened the heart, such as other cardiovascular diseases or even alcohol abuse.
Heart failure can be classified into left-sided and right-sided heart failure. Right
sided heart failure refers to systemic congestion and left heart failure refers to congestion
of the pulmonary veins. As the right ventricle fails to effectively pump the deoxygenated
blood into the left side of the heart, the blood starts backing up in the body's veins. This
leads to the collection of fluid in the lower extremities and eventually in the abdomen.
The weight gain that accompanies the fluid retention can be used to measure the amount
of fluid congestion. With left-sided heart failure, the left ventricle is unable to pump the
newly oxygenated blood out to the body and the lungs become congested with blood as a
result. Right-sided heart failure will often occur as a result of left-sided heart failure.
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Left-sided heart failure can be further differentiated into systolic and diastolic
heart failure. Systolic heart failure is characterized by the dysfunction of the left
ventricle. A clinical measurement of the left ventricular pumping capacity is the ejection
fraction (EF), a calculation of the proportion of the blood in the ventricle that is ejected
with each contraction of the left ventricle.
An EF of <40% is typically used to diagnose systolic heart failure. In heart
failure with preserved ejection fraction, or diastolic heart failure, the heart may contract
normally, but the left ventricle is unable to fill fully because it is stiff, therefore less
compliant to relax. This malfunction impedes the blood flow into the heart from the
lungs and produces backup in the lungs.
1. Remodeling <£ reverse remodeling
A major clinical marker of progressive heart failure is changes to the
heart on the cellular and molecular level. The changes that result in modification of the
heart size, shape and function define cardiac remodeling.2 Cardiac remodeling can also
occur after myocardial infarction, inflammatory heart muscle disease and other
etiologies.
The pathogenic mechanisms that lead to cardiac remodeling are unclear, but the
stress induced on the myocardial wall from persistent ventricular dilation may stimulate
the pathogenesis toward remodeling. The pathophysiologic changes in response to
cardiac injury include oxygen free radical fonnation which causes oxidative stress.
Increased levels of norepinephrine and continued activation of neurohormonal systems
lead to excessive vasoconstriction, volume expansion and left ventricular remodeling.
On a cellular level, myocyte hypertrophy, necrosis, apoptosis, fibrosis, increased fibrillar

3

collagen, proliferation of fibroblast and the increased circulation of angiotensin II are
involved. The usually elliptical-shaped heart becomes more spherical as the remodeling
progresses, with increases in ventricular mass, composition and volume.
The presence of major remodeling in heart failure patients is an indicator of poor
prognosis. The morphological change, initiated as a compensatory process, eventually
impedes the function of the heart and further becomes a maladaptive one. Changes in the
heart's size and shape can be measured to detect remodeling using several methods.
Measuring wall thickness or myocardial mass can give clues to changes in overall
cardiac structure. Left ventricular volume, ejection fraction, linear dimensions and
functional shortening can be measured to assess the extent of cardiac remodeling.
Reverse remodeling is a terminology used to describe the process in which the
heart is restoring back to its original state in function and structure. Clinical trials have
shown that reverse remodeling may be possible through certain drug therapies and this
will be discussed later. Improvements in ejection fraction read from echocardiograms
(echo) can detect presence of reverse remodeling.3
B. Classifications
The degree of heart failure progression can be classified in several different
ways. The most commonly used classification is the New York Heart Association
(NYHA) Functional Classification. The NYHA classifications are based on symptoms in
relation to physical activity. For example, there is no symptom limitation with ordinary
physical activity in NYHA Class I while Class IV indicates dyspnea at rest or with very
little exertion. Another HF classification system that is used is the American College of
Cardiology (ACC) and American Heart Association's stages A through D. Stage A
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denotes an absence of functional or structural heart disorder whereas Stage D indicates
advanced disease.3
C. Diagnosis
The criteria for heart failure diagnosis have historically been ambiguous because
of its varying definitions, which may have further led to heart failure being either
misdiagnosed or even overlooked in clinical settings. The clinical manifestations among
HF patients include multiple symptoms such as dyspnea when lying down or active,
persistent coughing or wheezing, edema in the lower extremities, fatigue, decreased
appetite, nausea, impaired thinking and increased heart rate. The ACC/AHA task force
asserts that heart failure is a symptomatic disorder.3 Initial assessment of patients with
HF usually involves difficulty with exercise tolerance due to dyspnea or fatigue, fluid
retention in their abdomen or legs, or the presence of another disorder, cardiac or
otherwise.
There is no one specific test for the diagnosis of heart failure, but there are
several tools used for a clinical diagnosis. A stress test on a treadmill may be used while
measuring the blood oxygen saturation or more invasive hemodynamic measurements
may also be used to isolate the cause for decreased exercise tolerance. Chest X-ray can
be used to detect buildup of fluid in the lungs or see any enlargements of the heart.
Electrocardiogram (ECG) results may be normal in HF, but can identify rhythm
disorders or other heart problems that are usually antecedent to heart failure. Levels of
sodium, potassium and other electrolytes can be measured to detect kidney disease, a
major risk factor for heart failure. Multiple-gated acquisition scanning (MUGA) can be
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done to assess the pumping perfonnance of the ventricles by tracking the path of the
radioactive dye through the heart.
Elevated levels of cardiac hormones can be used to diagnose HF because of the
disease's activation of the endocrine systems. The stretching of the ventricular wall, due
to volume and pressure overload, triggers the cardiac honnone system. Injury to the
heart increases the synthesis of atrial natriuretic peptide (ANP) and B-type natriuretic
peptide BNP and its release from atrial and ventricular myocardium.4 Cardiac troponin
in the serum may also be indicative of cardiac injury.5 Patients can be tested for elevated
plasma concentrations of ANP, BNP and cardiac troponins and their pro-hormones.
However, age and gender must be taken into consideration in combination with honnone
levels for a heart failure diagnosis to be detennined due to the nondiscriminatory
outcome of cardiac honnone changes.
Echocardiograms are most useful to look at various cardiac structures to
determine whether there are abnormalities of the myocardium, heart valves, or
pericardium. Ejection fraction, ventricular dimension, volume, wall thickness, chamber
geometry and regional wall motion are measured in echos. Left ventricular ejection
fraction (LVEF) is used to differentiate between diastolic or systolic heart failure
diagnoses.
D. Treatment
Treatments for heart failure range from lifestyle adjustments to drug therapy.
Heart failure patients are often advised to take on lifestyle changes including reduction
in sodium intake, smoking cessation and if necessary, weight loss. Diuretics are
prescribed to treat water retention. Effective drug therapies include beta-adrenergic
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blockade ((3-blocker), angiotensin converting enzyme inhibitors (ACEi) and angiotensin
II receptor blockers (ARB). The dosages of drug treatment for HF have not been
standardized until recently. The Heart Failure Society of America (HFSA) published
new guidelines in 2010 that recommended initial and target doses of (3-blockers, ACEi
and ARB to improve HF prognosis. The recommended target dosages are based on
successful outcomes of clinical trials and compliance of the recommended target dosages
that may enhance overall survival.
1. Clinical trials
Numerous clinical trials have established that (3-blockers increase survival
and improve prognosis of patients with HF. The MOCHA (multicenter oral carvedilol
heart failure assessment) study found that subjects treated with carvedilol, a (3-blocker,
experienced a reduction in all-cause mortality risk by 73% (p<.001) and a decrease in
hospitalization rate from 64% to 58% (p=0.10) compared to patients in the control
group.6 Another clinic trial of carvedilol found that there was a 65% attributable risk
reduction in mortality with (3-blocker usage (p<.001).7 It also found that carvedilol
therapy was associated with a 27% risk reduction in cardiovascular-related
hospitalizations (19.6 % vs. 14.1%, p=0.036) when compared with placebo. The Cardiac
Insufficiency Bisoprolol Study (CIBIS), a European, multicenter double-blind,
randomized placebo-controlled trial, was stopped early because bisoprolol significantly
lowered all-cause mortality (HR=0.66, 95% Cl 0.54-0.81).8 Very recent results from the
HF-ACTION (Heart Failure: A controlled Trial Investigating Outcomes of Exercise
Training) trial demonstrated that there was an inverse relationship between (3-blockers
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and all-cause mortality among systolic HF patients receiving up to 50mg of (3-blockers
per day.9
Studies have shown that reverse remodeling may also be achieved through (3blocker therapy. A clinical study of 142 HF patients found that left ventricular ejection
fraction independently predicted survival among its study cohort.10 It found that LVEF
improved from 30% ± 11% to 40% ± 13% after p-blocker treatment. Even after
accounting for P-blocker treatment, a positive change in LVEF independently improved
survival. Negative change in EF and having lower EF at baseline predicted a lower
survival rate. The MOCHA study also found a positive dose-response association
between stratified levels of carvedilol and EF units (p<.001).6
ACEis are prescribed to heart failure patients because it improves haemodynamics
by reducing the activity of the sympathetic nervous system and improving p receptor
densities. They decrease the degradation of the vasodilator bradykinin, thereby increasing
its concentrations. Studies have shown that ACEi improve exercise tolerance and overall
prognosis, although some adverse effects include angio-edema, dry cough and
hypotension.11
The Metoprolol CR/LX Randomized Intervention Trial in Heart Failure (MERITHF) study randomized men and women with symptomatic heart failure and depressed
LVEF to take metoprolol CR/XL or placebo. The results showed that all-cause mortality
was lower in the intervention group than in the placebo group (RR=0.66, 95% Cl 0.520.81). A larger, international clinical trial similarly found that subjects on enalapril, an
ACEi, experienced lowered all-cause mortality than those on placebo (HR=0.84, Cl 95%
0.74-0.95).12 The Studies of Left Ventricular Dysfunction (SOLVD) treatment was
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another clinical trial in which systolic heart failure patients, with or without chronic
kidney disease (CKD), were randomized into an enalapril intervention group or placebo
group. After an average of 41.4 months, results showed that the overall mortality among
those with CKD was lower for those on ACE inhibitors than those on placebo (HR=0.88,
95% Cl 0.73-1.06). Participants without CKD and on enalapril had a significantly lower
mortality than those on placebo (HR=0.82, 95% Cl 0.69-0.98). 13
Almost all of the clinical drug trials have been conducted on systolic heart failure
cohorts. Unfortunately, the effects of drug therapies have largely been inconclusive in
patients with preserved LVEF, 14-16 but there is some evidence that patients with diastolic
heart failure may benefit from drug therapies. The CHARM-Preserved Trial has shown
that, compared with placebo, being on ACEi or ARB lowers the risk of combined adverse
effects, including cardiovascular-related deaths.17 A study in the Netherlands, in which
patients with preserved left ventricular EF made up 60% of the inpatient study cohort.
found that all-cause mortality was lower among patients receiving (3-blockers compared
to those who did not use this medication (17.6% vs. 33.8%).16
Our study at Loma Linda Medical Center (LLUMC) explored the outcomes of the
uptitration of p-blocker, ACEi and ARB dosages on an unselected population of heart
failure patients. The study investigated the applications of drug therapy recommendations
to see if results from the clinical trials were similar in an ordinary, clinical setting.
E. Epidemiology
/. Prevalence & Incidence
Over 5 million Americans live with heart failure today and the lifetime
risk of heart failure in the US is 1 in 5 among men and women at age 40.18 A 44-year
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follow-up study found that yearly HF incidence is nearly 10 per 1000 persons after the
age of 65.19 According to the Heart, Lung, and Blood Institute, the yearly rate of new HF
events per 1000 persons for white men between ages 65 and 74 is 15.2, 31.7 for those
between 75 and 84 years of age and increases to 65.2 for ages 85 and older.20 For black
men in the same age categories, it is 16.9, 25.5 and 50.6, respectively. White women
between ages 65 and 74 had an annual rate of new HF events of 8.2 per 1000 persons
while black women had 14.2. Between 75 and 84 years, white women had an annual
incidence of 19.8 per 1000 persons and black women had 25.5 per 1000 persons. The
rate among white women in the oldest age category was 45.6 per 1000 compared to the
rate of 44.0 per 1000 among black women.
A retrospective cohort study on elderly persons on Medicare estimated that the
incidence of heart failure was 29 per 1000 person-years in 2003. Between the years 1994
and 2003, the incidence among beneficiaries 65 to 69 years of age increased from 17.5
per 1000 person-years to 19.3 per 1000 person-years while the incidence of beneficiaries
80 to 84 years of age decreased from 57.5 per 1000 person-years to 48.4 per 1000
91

person-years.“ The Medicare enrollees had a risk-adjusted 1-year mortality rate of
27.5% (95% Cl 27.1-27.9) and had more than three times higher mortality due to heart
failure compared to the general population, with a standardized mortality ratio (SMR) of
3.3 in 2002.21 Among the HF study cohort at LLUMC, the total mortality rate was 24.3%
in the study's 4-year duration.
There is growing evidence that the incidence of diastolic heart failure is
increasing. The Framingham Heart Study found that the average prevalence of heart
failure with preserved EF increased from 38% to 47% to 54% during a 15-year span, in
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which the average age among those with HF and preserved EF was 74.4 years and the
HF diagnosis with preserved EF accounted for 49% among those 65 years and older.22 A
cross-sectional study of the asymptomatic population of Olmsted County in Minnesota
found that 21% had mild diastolic dysfunction and 7% had moderate to severe diastolic
dysfunction. A total of 6% had moderate to severe diastolic dysfunction with normal
ejection fraction and a total of 6% had systolic dysfunction.23 Diastolic heart failure
patients accounted for nearly 44% of the HF population at LLUMC and 35.43% of the
diastolic HF population were over 75 years of age. The study cohort was an unselected
population in order to explore treatment opportunities in real-life, prevalent heart failure
populations, including a substantial number of diastolic HF patients.
The biggest burden of heart failure lies with its associated hospitalizations. Heart
failure as the primary reason for hospitalizations has tripled in recent years and the direct
and indirect costs of HF are estimated to be over $33 billion per year. 18,24 Because
effective treatments of HF can be ambiguous due to complex etiologies of the disease,
controlling the risk factors may be a good strategy to curtail the increasing incidence of
HF.
2. Important risk factors
One of the leading risk factors of HF is hypertension. The lifetime risk for
HF doubles for person with blood pressure greater than 160/90 mm Hg compared to
those less than 140/90 mm Hg.~ Among 5,143 Framingham Heart Study participants,
aged 40 to 89 years, 392 developed heart failure during the 20.1 years of follow-up and
91% of the incidences were subsequent to hypertension.2'^ Hypertensive men were twice
as likely to develop heart failure compared to normotensive men and hypertensive
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women had three times the risk as normotensive women, after adjusting for age and
other heart failure risk factors. Hypertension accounted for 39% of heart failure in men
and 59% in women. And the 5-year survival of HF with hypertension etiology was
calculated to be a mere 24% for men and 31 % for women.
Diabetes is also one of the strongest risk factors and comorbidities of HF. Heart
failure patients with diabetes have higher prevalence of coronary artery disease,
hypertension and obesity. 26 The increase in circulating free fatty acids may play a
significant part in the myocardial dysfunction, among other biochemical events that
characterize diabetes.
Many studies, including the Cardiovascular Health Study (CHS), have found that
there is a significantly higher independent risk for incident heart failure with diabetes. 27
A collaborative study that combined multiple databases found that the incidence of HF
was two times higher among subjects with baseline diabetes compared to those
without. 28 Results showed that women without diabetes had an annual incidence rate of
0.4% compared to the annual incidence of 3% of diabetic women with no additional risk
factors. The addition of any risk factor with diabetes greatly increased the incidence of
HF. Diabetic women with elevated BMI had a rate of 7% and diabetic women with
depressed creatinine clearance had a 13% annual incidence rate. Overall, the incidence
increased to 8.2% for diabetic women with at least 3 additional risk factors.
Coronary artery disease (CAD) is a significant contributor of heart failure. It is a
disease in which the plaque buildup in the coronary arteries restricts blood flow into the
heart. A British study assessed the importance of the role that coronary artery disease
played in heart failure etiology. CAD was identified as the primary etiology for 29% of
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all cases of heart failure and 40% of incident cases under 75 years of age.29 The
Framingham study attributed CAD as the primary cause of heart failure in their
participants in 59% of men and 48% of women.19
Renal disease is a common condition among patients with heart failure and is a
major contributor to its poor prognosis. HF subjects with renal dysfunction are at
significantly increased risk of HF hospitalization and mortality. Renal disease was a
significant predictor of mortality among our systolic HF population at LLUMC. The
development of renal failure may be mitigated by the use of diuretics by the upregulation of the renin-angiotensin aldosterone system, further promoting basal
sympathetic nerve discharge and increases in pro-inflammatory factors, which may
eventually lead to impaired volume handling and pump failure. 30.31 It is plausible that
renal dysfunction is also a marker for worsening HF. There is also a high prevalence of
renal dysfunction due to multiple unifying risk factors that associates heart failure with
renal dysfunction such as advanced age, hypertension and diabetes.32
3. Modifiable risk factors
Recent studies have focused on the risk of heart failure and lifestyle
factors. Healthy lifestyle habits such as normal body weight, not smoking, regular
exercise, moderate alcohol intake, consumption of grains, fruits and vegetables may
modify risk of HF incidence.33
Clinic trials have long since established the benefits of omega-3 polyunsaturated
fatty acids (co-3 PUFA), found in fish oil, for the prevention of coronary heart disease.
Two major randomized controlled trials showed that participants on co-3 PUFA
supplementations experienced a 15% reduction in primary end points, which included
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30% reductions of cardiovascular mortality, compared to usual care.34 The
Cardiovascular Health Study (CHS), a population-based study, found an inverse
association between baked or broiled fish consumption and incident HF and also
improved cardiac hemodynamics such as lower heart rate, lower systemic vascular
resistance and greater stroke volume.35 In another study, men who ate a moderate
amount of fatty fish and omega-3 fatty acids, once per week, had an HR of 0.88 (95% Cl
0.68-1.16) for incident heart failure compared to those with no fatty fish or omega-3fatty acid consumption.36
The Physicians’ Health Study found that there was a significant positive
relationship between red meat consumption and incident heart failure among men. Those
in the highest quintile of meat consumption experienced a 24% increase in risk
compared to no consumption.37 The study also found that healthy lifestyle habits, which
included normal body weight, not smoking, regular exercise, moderate alcohol intake,
eating breakfast cereals, fruits and vegetables, were individually and jointly associated
with lower lifetime risk of heart failure. Several studies, including the Atherosclerosis
Risk in Communities (ARIC) Study, found that greater consumption of high fat dairy,
eggs and low intake of whole grains were associated with a higher incidence of HF.38
Nut consumption has proven to be effective in decreasing risk of cardiovascular disease,
but the benefits of nuts in preventing heart failure is not as clear. The Physicians' Health
Study I, for example, failed to show a significant relationship between nut intake and
incident heart failure.33
Studies have consistently shown that there is an association between moderate
drinking and lower risk of cardiovascular disease, but there is limited data on its
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relationship with heart failure. Multivariate models from the Physicians’ Health Study
found that alcohol consumption was significantly associated with a lower risk of HF
with a dose response relationship among men with hypertension.39
Data on modifiable risk factors were not collected in the cardiomyopathy clinic
at LLUMC, but it may be important to address these important risk factors in future
research in order to fully describe the prognosis of its patients in regards to drug
therapies.
F. Validity of self-reported heart failure
Large epidemiologic studies are essential in identifying risk factors of heart
failure in order to work towards heart failure prevention. These studies rely on selfreported, but physician diagnosed, disease statuses. Validity of self-reported diseases
likely depends on disease type, questionnaire design, population characteristics and other
factors. It is therefore important to assess validity in the individual studies.
Few studies have measured the validity of self-reported heart failure. Among 51
self-reported cases of heart failure, the Olmsted Study found a sensitivity of 68.6%,
specificity of 97.0%, accuracy of 96.3%, but heart failure was only validated through
medical records in half of self-reports3 giving a Positive Predictive Value (PPV) of about
50%. The Medicare Administrative and Health and Retirement Study (HRS) had a low
sensitivity (25.2%) with a total agreement of 87.7%.40 The study also found that Blacks
and Hispanics were less likely to self-report CHF compared to whites (ORBiacks=0.28,
95% Cl 0.14-0.55, ORHispanics=0.30, 95% Cl 0.11- 0.83).

Okura et al. found that advanced age (OR=0.22, 95% Cl 0.13-0.37), a Charlson
index greater than 1 (OR=0.10 95% Cl 0.05-0.2), medical records archived older than 36
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years (OR=0.60, 95% Cl 0.37-0.97) predicted a lower agreement between self-reports of
heart failure on questionnaires and medical records. The female gender (OR=3.14, 95%
Cl 1.87-5.27) and education level attained greater than 12 years (OR=2.60 95%, Cl 1.614.19) predicted a higher agreement between questionnaire and medical record. The AHS2 validation study also looked at the associations of demographic characteristics and the
agreement between self-reports and medical records.
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Abstract
Background
Heart failure (HF) is a disease with considerable burden on the US population due to its
high hospitalization and mortality rates. Clinical trials have shown that drug therapies
with (3-adrenergic blockade ({3 blocker), angiotensin converting enzyme inhibitors (ACEi)
and angiotensin II receptor blockers (ARB) improve HF prognosis but there are few
studies that show outcomes of such drug therapies in real-life populations with prevalent
heart failure.
Methods and Results
This prospective study was conducted at the Loma Linda University Medical Center
cardiomyopathy clinic to assess the effect of drug therapies on an unselected heart failure
outpatient population.
A total of 292 subjects with prevalent CHF were followed for 4 years. At the end of the
study, 71 (24.3%) were deceased. Those who survived tended to be younger, have lower
NYHA class, were more likely to have been at target dosages of p-blockers and ACEi or
ARBS, less likely to have used diuretics and less likely to have a history of renal disease.
Results from multivariable analysis suggest that reaching target dosages of p-blocker,
ACEi/ARB may improve survival among systolic HF patients (HRp.bi0cker= 0.64, 95% Cl
0.26-1.55 and HRacei arb=0.50, 95% Cl 0.22-1.14) and survival among diastolic HF may
also be enhanced with (3-blocker therapy (HR= 0.48, 95% Cl 0.13-1.81) and ACEi/ARB
therapy (HR =0.21,95% Cl 0.04-1.07).
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Conclusions
This study showed that treatments with recommended target dosages of p-blockers.
ACEi/ARB seemed to improve survival among both systolic and diastolic HF patients.
Key words
Heart failure, p blockers, ACEi, ARB, systolic heart failure, diastolic heart failure
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Introduction
There are almost 6 million people living with heart failure (HF) in the US today.20
The lifetime risk of HF at age 40 for both men and women is 1 in 5.23 As heart failurerelated hospitalizations have tripled in recent years, it is one of the most common reasons
for hospitalizations and the direct and indirect costs of HF are estimated to be over $33
billion per year. 41 Efficient and comprehensive treatment of heart failure is necessary to
stem its devastating impact on the health of the US population.
Clinical trials have shown that p-adrenergic blockade (p-blockers), angiotensin
converting-enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) in
patients with severe systolic HF can reduce mortality and improve symptoms. The Heart
Failure Society of America's (HFSA) recently published executive summary on heart
failure practice guideline provides a standardization to HF treatment.42 The summary
recommends initial and target doses of P-blockers and angiotensin converting enzyme
inhibitors/angiotensin II receptor blockers (ACEi/ARB) for the enhancement of HF
survival and prognosis but its real-world applications have not yet been well studied.
This prospective study is based on a comprehensive review of all patients seen
with a diagnosis of HF at Loma Linda University Medical Center (LLUMC)
cardiomyopathy clinic with a 4-year follow-up. We assessed survival according to use
and target dosages of p-blocker and ACEi/ARB treatment in this unselected patient
population.
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Methods
Study population
The study population included a total of 292 consecutive outpatients who were
seen in the LLUMC cardiomyopathy clinic from January to July 2006 and followed up
through the end of December 2010. Patients with congenital etiologies or without follow
up data were not included in the study. Systolic heart failure was defined as an ejection
fraction (EF) below 40% at enrollment while patients with EF of 40% and above were
classified as having diastolic heart failure, also known as heart failure with preserved EF.
Results of all echocardiograms (echos) and medical infonuation, such as heart
rate, weight, blood pressure, and medication list, from the first clinic visit and from visits
approximate in time to when echos were performed were extracted from the medical
records at LLUMC. B-blockers, ACEi and ARB dosages that were prescribed at least one
month prior to the corresponding echos were recorded. Patients usually received a yearly
echo but 92 patients had only one echo done at LLUMC during the time of the study.
Patients’ most current EFs were used as a predictor of their survival.
While patients were already on (3-blocker, ACEi or ARB when they were referred
to LLUMC, their dosages were uptitrated to the most tolerable levels in order to reach
target dosages, as recommended by HFSA. Patients who were not able to tolerate ACEi
were put on ARB.
Deaths were notified from LLUMC, skilled nursing facilities and families and
were all confirmed through the Social Security Death Index (SSDI). The SSDI was
checked annually for patients who were not seen by the clinic in over a year.
This study was approved by the Institutional Review Board of Loma Linda University.
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Statistical analysis
Chi-square analysis compared the differences between potential covariates among
participants who survived and those who did not.
Multivariable Cox regression was performed to assess survival in the study population,
with attained age at study enrollment as the time variable. Regression models were
developed separately for those with systolic heart failure and those with diastolic heart
failure.
Demographic variables including gender, smoking history and race/ethnicity were
considered as confounders in the model as were NYHA functional class, Body Mass
Index (BMI) and heart failure etiology (ischemic and non-ischemic). Other candidate
confounders were comorbidities such as history of hypertension, renal disease, diabetes
and dyslipidemia, as well as heart rate and systolic and diastolic blood pressure around
the time of the most recent EF.
Demographic confounders and comorbidities were assessed individually as
predictors of survival and then considered in combinations with p-blocker and
ACEi/ARB treatments. Variables that changed the effect of the medications (p-blockers,
ACEi/ARB) more than 10% or more were significant predictors of survival were
considered for the final model along with P-blockers and ACEi/ARBs. The proportional
hazards assumption was satisfied through the evaluation of negative log-log plots.
Schenfelds residual plots, and the absence of time interactions. Continuous covariates
were assessed for linearity through Martingale residuals plots and by plots of residuals
against individual covariates.
All statistical analyses were performed using SAS/STAT® software.
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Results
Descriptive analysis
Of the 292 subjects, 71 (24.3%) were deceased as of the end of December 2010. The
characteristics of the overall study population, comparing those who survived through
2010 to those who did not, are described in Table 3.1. Those who survived tended to be
younger and have lower NYHA class. Subjects who survived were more likely to have
been at target dosages of p-blockers and ACEi or ARBs, less likely to be using diuretics
and less likely to have a history of renal disease.
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Tabic 3.1 Descriptive characteristics of study population at baseline
Total
Non-survival
Survival
(%)

Gender
Men
Women
Age
<60
60-75
75+
Race/ethnicity
Black
Hispanic
White, others
Smoking history
Never smoker
Past smoker
Current smoker
NYHA class
2
3,4

(%)

(%)

34 (47.89)
37 (52.11)

P value

154(52.74)
138 (47.26)

120(54.30)
101 (45.70)

0.36

113 (38.70)
98 (33.56)
81 (27.74)

80 (36.20)
76 (34.39)
65 (29.41)

48 (16.44)
52 (17.81)
192 (65.75)

36(16.29)
37 (16.74)
148 (66.97)

145 (49.83)
131 (45.02)
15(5.15)

107 (48.42)
103 (46.61)
11(4.98)

43 (19.37)
60 (27.03)
119 (53.60)

42 (24.56)
49 (28.65)
80 (46.78)

1(1.96)
11 (21.57)
39 (76.47)

<0.01

119(40.89)
85 (29.21)
87 (29.90)

85 (38.46)
63 (28.51)
73 (75.95)

34(48.57)
22 (31.43)
14(20.00)

0.12

14 (19.72)
<0.01
21(29.58)
36(50.70)
12 (16.90)
15 (21.13)
44 (61.97)
38 (54.29)
28 (40.00)
4(5.71)

0.67

0.62

BMI
Slim-normal (<24)
Overweight (25-29)
Obese (>30)
Type
Systolic
Etiology
Ischemic
Non-ischemic
Diastolic (EF>40)
Etiology
Ischemic
Non-ischemic
Beta-blocker dose
Target
Below target
No use
ACEi dose
Target
Below target
No use

69 (57.67)
94 (57.67)
127(43.79)

53 (38.97)
83 (61.03)

20 (50.00)
20 (50.00)

0.21

31 (25.20)
92 (74.80)

20 (24.69)
61 (75.31)

7 (23.33)
23 (76.67)

0.88

92 (32.39)
169 (59.51)
23 (8.10)

60 (27.52)
145 (66.51)
13 (5.96)

11(16.67)
45 (68.18)
10 (15.15)

0.02

98 (35.64)
96 (34.91)
81 (29,45)
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83(39.71)
15 (23.44)
71(33.97)
23 (35.94)
55(26.32)
26 (40,63)

0.03

Table 3.1 (continued) Descriptive characteristics of study population at baseline
Total
NonSurvival
P value
survival (%)
(%)
(%)
ARB dose
Target
36 (13.53)
30 (14.85)
6(9.38)
0.41
Below target
43 (16.17)
34 (16.83)
9(14.06)
No use
187 (70.30)
138 (68.32)
49 (76.56)
Diuretics
Use
87 (29.79)
55 (24.89)
32 (45.07)
<0.01
Nonuse
33 (11.30)
25 (11.31)
8(11.27)
Unknown
172 (58.90)
141 (63.80)
31 (43.66)
Comorbidity history
Hypertension
206 (70.55)
160 (72.40)
46 (64.79)
0.22
Type II Diabetes
98 (33.56)
68 (30.77)
30 (42.25)
0.08
Dyslipidemia
136 (46.58)
108 (48.87)
28 (39.44)
0.17
Renal disease
53 (18.15)
32 (14.48)
21 (29,58)
<0.01

Characteristics between systolic and diastolic HF population are described in
Table 3.2. Patients with diastolic heart failure were more likely to be female and older
than those with systolic HF. There were no current smokers in the diastolic HF
population. Systolic HF patients had HF with ischemic etiology and were more likely to
be at the target (3-blocker dosage compared to the diastolic HF patients. A larger
proportion of patients with diastolic HF had a history of hypertension and renal disease.

Table 3.2. Descriptive characteristics of study population at baseline between
systolic and diastolic heart failure populations
Systolic (%)
Diastolic (%)
P value
Gender
Men
97 (59.51)
55 (43.31)
<0.01
Women
66 (40.49)
72 (56.69)
Age
<60
71 (43.56)
42 (33.07)
0.03
60-75
56 (34.36)
40 (31.50)
75+
36 (22.09)
45 (35.43)
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Table 3.2 (continued) Descriptive characteristics of study population at
baseline between systolic and diastolic heart failure populations
Systolic (%)
Diastolic (%)
Race/ethnicity
Black
32 (19.63)
16(12.60)
Hispanic
25 (15.34)
26 (20.47)
White, others
106 (65.03)
85 (66.93)
Smoking history
Never smoker
72 (44.17)
72 (57.14)
Past smoker
76 (46.63)
54 (42.86)
Current smoker
15 (9.20)
0 (0.0)
NYHA class
1
65 (53.72)
53 (53.54)
2
29 (23.97)
31 (31.31)
3,4
27 (22.31)
15 (15.15)
BMI
Slim-normal (<24)
73 (44.79)
46 (36.51)
Overweight (25-29)
46 (28.22)
39 (30.95)
Obese (>30)
44 (26.99)
41 (32.54)
Type
Ischemic
69 (42.33)
31 (25.20)
Non-ischemic
94 (57.67)
92 (74.80)
p-blocker dose
T arget
60 (37.27)
31 (25.62)
Below target
93 (57.76)
75 (61.98)
No use
8 (4.97)
15 (12.40)
ACEi dose
Target
61 (38.85)
35 (30.17)
Below target
55 (35.03)
41 (35.34)
No use
41 (26.11)
40 (34.48)
ARB dose
Target
17(11.18)
19(16.81)
Below target
23 (15.13)
19(16.81)
No use
1 12 (73.68)
75 (66.37)
Diuretics
Use
52 (31.90)
35 (27.56)
Nonuse
15 (9.20)
18(14.17
Unknown
96 (58.90)
74 (58.27)
Comorbidity history
Hypertension
105 (64.42)
99 (77.95)
Type II diabetes
57 (34.97)
40 (31.50)
Dyslipidemia
77 (47.24)
58 (45.67)
Renal disease
23 (14,11)
30 (23.62)
26

P value
0.20

<0.01

0.28

0.35

<0.01

0.02

0.22

0.35

0.37

0.01
0.53
0.79
0.04

The causes of death in this population were largely unknown (Table 3.3).
Table 3.3 Causes of death
Total=71
Progressive Heart Failure
Non-cardiac
Unknown/other

Total (%)
11 (15.49)
16 (22.54)
44 (61.97)

Survival analysis
The comparison of the systolic and diastolic HF population survival curves in
Figure 3.1 show that patients with diastolic HF had better survival than patients with
systolic HF.
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Figure 3.1 Survival curve comparison of systolic and diastolic heart failure populations
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When assessed individually in univariate Cox regression models, NYHA stage 3
and heart rate were associated with higher hazard rate whereas EF and use of p-blockers
were associated with better survival among patients with systolic heart failure and to a
lesser degree in diastolic HF. Use of ACEi/ARB, on the other hand, was more strongly
associated with lower hazard rate in diastolic HF (Table 3.4). Of the recorded
comorbidities, prevalent kidney disease was associated with higher mortality among
patients with diastolic HF.
The final model (Table 3.5) for the systolic HF population suggests that reaching
target dosages of both p-blockers and ACEi/ARB may increase survival compared to not
reaching target, although not significant (HRpbiocker= 0.64, 95% Cl 0.26-1.55 and
HRACEi/ARB=0.50, 95% Cl 0.22-1.14). Ejection fraction and being of Hispanic
race/ethnicity were both strong and independent predictors of survival. There was almost
a 25% decrease in mortality with every 5% increase in EF (HR= 0.95, 95% Cl 0.92-9.98).
Hispanic ethnicity predicted almost a 4-fold increase in mortality compared to all other
ethnicities with a hazard ratio of 3.90 (95% Cl 1.41-10.78).
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Table 3.4. Univariate models

Hispanic
Female
Past/current smoker
NYHA Class 3+
BMI
Ischemic etiology
Comorbidity history
Hypertension
Renal disease
Type II Diabetes
Dyslipidemia
Heart rate
Hypertensive
Systolic Blood
Pressure>140
Diastolic Blood
Pressure>90
SBP>140 or DBP>90
Ejection fraction
P-blocker dose
below target
at target
ACEi/ARB
below target
at target

Systolic I IF Population
Hazard
95% Cl
Ratios
2.40
5.91
0.98
1.38
0.70 2.73
0.44
1.72
0.87
3.17
1.19 8.46
0.91
0.95
1.00
1.41
0.70 2.85

Diastolic HF Population
Hazard
95% Cl
Ratios
1.07
0.44 2.61
0.41
0.88
1.92
0.34
1.67
0.75
4.97
1.33
18.5
1.01
0.96
1.06
0.89
0.35
2.28

0.43
1.23
1.95

0.22
0.52
0.92

0.85
2.90
4.17

0.88
3.06
1.44

0.33
1.31
0.63

2.34
7.14
3.26

0.55

0.27

1.13

0.88

0.40

1.92

1.03

1.00

1.05

1.04

1.00

1.08

1.13

0.49

2.59

1.01

0.40

2.53

2.32

0.63

8.53

0.84

0.10

7.39

1.26
0.96

0.56
0.93

2.82
0.99

1.01
1.00

0.40
0.97

2.53
1.03

0.51
0.96

0.27
0.93

0.96
0.99

0.59
1.00

0.27
0.97

1.28
1.03

0.62
0.31

0.25
0.11

1.58
0.86

0.12
0.17

0.03
0.03

0.54
0.82

Table 3. 5. Final survival models
Systolic HF Population
Hazard Ratios
(3-blocker target vs nontarget
0.64
ACEi/ARB target vs. nontarget
0.50
Hispanic
3.90
EF
0.95
Diastolic HF Population
Hazard Ratios
[3-blocker any vs none
0.48
ACEi/ARB any vs none
0.21
Renal disease
3.68
29

95% Cl
0.26
1.55
0.22
1.14
1.41
10.78
0.92
0.98
95% Cl
0.13
1.81
0.04
1.07
1.39
9.74

Although not reaching statistical significance, use of p-blockers and ACEi/ARB
treatments independently suggests a decrease in mortality in the final model among
diastolic HF patients (HRpblocked 0-48, 95% Cl 0.13-1.81 and HRAcEi/ARB=0.21, 95% Cl
0.04-1.07) (Table 5). History of renal disease among the diastolic HF patients strongly
predicted mortality with a hazard ratio of 3.68 (95% Cl 1.39-9.74).
Discussion
Our study has demonstrated that reaching target dosages of P-blockers and
ACEi/ARB may independently enhance survival among systolic HF patients in this
unselected, prevalent heart failure population. This is in agreement with clinical trials that
have consistently shown that P-blockers, ACEi and ARBs significantly decrease all-cause
mortality in patients with systolic heart failure with similar point estimates as in our
study. Most recently, the HF-ACTION (Heart Failure: A controlled Trial Investigating
Outcomes of Exercise Training) trial demonstrated that there was an inverse relationship
between P-blockers and all-cause mortality among systolic HF patients receiving up to
50mg carvedilol or equivalent per day.9 Due to random assignments of drug treatments,
subjects in clinical trials are usually comparable in their exposure to other medications
but the effect of one medication in the presence of another has not been explicitly
described or tested as in our study.
The effects of drug treatments on the prognosis of subjects with preserved
ejection fraction have mostly been inconclusive. 14,

15

The CHARM-Preserved Trial has

shown that being on ACEi or ARB lowers the risk of combined adverse effects, including
cardiovascular-related deaths, compared with placebo.4'1 A study of an inpatient cohort in
The Netherlands, in which 60% had preserved left ventricular EF, found that all-cause
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mortality was lower among patients receiving (3-blockers than those who were not (17.6%
vs. 33.8%).16 Diastolic HF patients in this study experienced considerably lower mortality
with drug therapies. The increase in survival was seen with both (3-blocker and ACEi/
ARB therapies. More research on the effects of drug treatments in diastolic heart failure
is crucial due to the increased prevalence among the general population and the lack of
improvement in survival.
Increased ejection fraction during follow-up was a strong predictor of better
survival in the systolic HF population of our study. Improvement in EF, referred to as
cardiac reverse remodeling, was evident in the MOCHA (multicenter oral carvedilol heart
failure assessment) study that reported a positive dose response relationship between
higher doses of (3-blockers and EF.6 Increases in ejection fractions may be an approach to
quantify possible reverse remodeling, which may in fact translate to better survival and
prognosis in people living with heart failure. Studies have shown that positive change in
EF are associated with increased survival rates 44 and furthennore that (3-blockers and
ACEi may aid in the reduction of ventricular mass and thus mitigate reverse modeling. 6,
45

~ Our data analysis suggests that improvements in EF may also be associated with

survival, independent from drug treatments.
According to a 2005 study of Medicare enrollees, Hispanic Americans are one of
the fastest growing segments of the US population46 and thus it is important to note that
mortality among Hispanics in our study population is much greater than the other race
ethnicities.47 The Hispanic population is at higher risk of known risk factors of heart
failure than other race ethnic groups. The prevalence of diabetes among Hispanics is
twice that of other racial ethnic groups, with poorer glycemic control.48 More Mexican-
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American men and women are overweight or obese than non-Hispanic whites and the
prevalence of metabolic syndrome is higher than in non-Hispanic Whites (31.9% vs.
23.8%) or African Americans (21.6%).49 Mexican Americans have high prevalence of
hypertension, with poorer blood pressure control, and less medication treatment (35%)
compared to African Americans (57%) and non-Hispanic whites (54%).50 While these
individual risk factors did not significantly predict survival in our study population, the
poor survival seen in Hispanics may have been due to a combined effect of co
morbidities and less access to state of the art medical care. It is also possible that
medication adherence may be poor in the Hispanic population.
Renal disease is an important non-cardiac comorbidity in HF and was a strong
predictor of mortality among the diastolic HF patients in this study. HF subjects with
renal dysfunction are at significantly higher risk for HF hospitalization and mortality.32 It
is plausible that renal dysfunction is a marker for worsening HF but there is also a high
prevalence of renal dysfunction due to multiple unifying risk factors that associates heart
failure with renal dysfunction like older age, hypertension and diabetes. Another factor
implicated in the development of worsening renal failure is the use and overuse of
diuretics among HF patients. This can be explained by the theory that the up-regulated
renin-angiotensin aldosterone system promotes basal sympathetic nerve discharge.
increasing pro-inflammatory factors and eventually leading to impaired volume handling
and pump failure. 30. 31
Limitations
Due to small numbers, many of our findings did not reach statistical significance.
A longer follow-up time or larger number of HF patients is recommended in order to give
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adequate power for more firm conclusions, especially with respect to the effect of these
medications on the prognosis of the diastolic HF populations.
Conclusion
This study investigated the effectiveness of drug therapy in improving overall
survival on an unselected patient population with HF at a hospital heart failure clinic.
Results from data analysis showed that treatment at recommended target doses of P~
blocker, ACEi and ARB may improve survival among both systolic and diastolic HF
patients. Because there is little research data on the diastolic heart failure population, it is
noteworthy that our study shows that drug therapy reduces mortality in patients with
preserved EF. These findings can provide reassurance to clinicians that it is worthwhile to
push to reach recommended target dosages in treating patients with heart failure from low
to normal ejection fractions.
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Abstract
Purpose
The purpose of this study was to validate self-reported, physician-diagnosed congestive
heart failure (CHF) in the Adventist Health Study-2 (AHS-2) population.
Methods
Among 947 AHS-2 participants who reported that they were diagnosed with CHF on the
baseline questionnaire, 200 were randomly selected as cases and 260 were selected as
comparative non-cases among participants who said they did not have CHF. Medical
records containing sufficient infonuation of a physician diagnosis of CHF were requested
for all cases. Phone surveys were conducted for non-cases and medical records were
requested when necessary.
Results
Successful contact and validation was obtained from a total of 67 cases and XXX non
cases. Sensitivity was calculated to be 97.4%, specificity was 83.4%, negative predictive
value (NPV) was 99.3%, positive predictive value (PPV) was 56.7% and the total
agreement (accuracy) was 86.0 %.
Conclusions
Although sensitivity and NPV was excellent, the PPV was moderate. Self-reported
congestive heart failure in the AHS-2 cohort needs further study with a larger number of
cases and non-cases before reliable estimates of validity of self-reported physician
diagnosed CHF can be determined.
Keywords
Congestive heart failure, self-report, validation study, Adventist Health Study
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Background
As of 2010, approximately 5.8 million people in the United States are currently
living with congestive heart failure (CHF) and 670,000 are diagnosed every year.1 One of
five people diagnosed with CHF die within a year of diagnosis and the cost of health
care, medication and loss of productivity equates to a loss of $39.2 billion in the United
States.
Many epidemiologic studies use self-reported disease status to measure disease
outcomes in subjects because of its cost-effectiveness. Validity will most likely depend
on factors such as disease type, questionnaire design and study population. As a result,
many prospective studies conduct validity studies to assess the accuracy of self-reported
disease in their respective questionnaires. Establishing the accuracy of self-reported
disease outcomes will greatly improve the quality of studies that use these disease
statuses as their dependent variables.
The validity of self-reported CHF in the Adventist Health Study-2 (AHS-2)
cohort has not yet been established. The purpose of this study was to validate selfreported, physician-diagnosed congestive heart failure in the AHS-2 population.
Methodology
Study population
The Adventist Health Study-2 is an ongoing, longitudinal cohort study
investigating the association between lifestyle, diet, disease and mortality among more
than 96,000 participants from the United States and Canada. Subjects who indicated that
they have congestive heart failure by answering “‘yes" to ‘“Have you been treated for
congestive heart failure in the last 12 months?” and also replied to the "Years since first
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diagnosis [of congestive heart failure]’' question on the baseline questionnaire were
considered cases. A total of 947 reported prevalent CHF at baseline.
Of these 947 self-reports, 200 were randomly selected as cases and 260
participants who stated they did not have CHF and who were older than 50 years of age
were randomly selected as comparable non-cases using SAS® software. The National
Death Index (NDI) and Social Security Index (SSI) were checked for any deceased
participants.
Methods
All selected subjects were initially contacted by phone (Al) to inquire as to
willingness to release medical records pertaining to their potential CHF diagnosis. If
phone numbers were not current, we contacted the person listed as a contact on the
baseline questionnaire. If we were still not successful in contacting them, extensive
searches in online phone registries were done to attempt to locate them. At least six
phone call attempts were made if first contact was unsuccessful.
Follow-up of cases
Willing case participants were mailed a letter of correspondence containing an
infonued consent form (A2), information form for their current cardiologist and/or family
physician, infonuation form of their most recent hospitalization for heart failure and a
short questionnaire on CHF symptoms, heart medication and past echocardiograms
(echos).
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Follow-up of non-cases
Non-cases were asked to answer a short survey over the phone (A3) with the
following questions:
1. Have you ever been told by a physician that you have congestive heart failure or
CHF?
2. Have you experienced regular swelling in your lower extremities within the last 5
years?
3. Have you experienced regular shortness of breath with exertion or when you’re lying
down within the last 5 years?
4. Are you currently taking any heart medicines such as beta blockers, diuretics, ARB,
or ACE-inhibitor medications? Do you know why you are taking these?
5. Have you had an echo or a heart ultrasound?
Subjects who answered “yes” to question 1 or “yes” to combinations of either 2 or
3 with either 4 or 5 were asked if they were willing to sign a consent fonn for the release
of their medical records. The same correspondence that was mailed to cases was mailed
to willing non-cases whose medical records were required.
For the deceased population, the locations of medical records were sought through
contacting next of kin and churches of affiliation. A minimum of 6 phone attempts were
made for any unresponsive individuals, on different days of the week and different times
of the day, leaving at least 3 voicemails.
When the consent forms were mailed back, a request of information (ROI) were
faxed or mailed to their respective cardiology clinics or hospitals. The medical records
department or the physicians of the consenting participants were contacted with a letter
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from AHS-2 (A4) and a copy of their patients’ consent forms. Informed consent was
obtained from deceased participants at baseline. The ROI asked for a verification of a
CHF diagnosis around the time of AHS-2 enrollment through a combination of clinic
notes, echos, electrocardiograph (ECG), brain natriuretic peptide (BNP) levels,
medication list and a date of diagnosis. A short questionnaire (A5) on the presence of
dyspnea and edema in the patient was also included. If there was no evidence of CHF
diagnosis, physicians were asked to mark a statement confirming that their patient had
never been diagnosed with congestive heart failure.
Processing of medical records
Trained research personnel reviewed medical charts for CHF diagnosis validation
and a board certified cardiologist was responsible for the final quality control of the
medical records review. Explicit statements of CHF diagnosis in clinic notes qualified as
a positive validation. Without clinic notes, test results such as echos and ECGs, along
with the presence of dyspnea and edema qualified as validation of CHF diagnosis. Any
CHF diagnosed after the date of baseline questionnaire completion were not included as
confirmation of self-reported CHF.
Statistical methods
Chi-square frequency test was performed to evaluate representativeness of the sample
population to the entire AHS-2 cohort. Sensitivity was calculated as (TP)/(TP+FN) and
specificity was calculated as (TN)/(TN+FP). Accuracy was calculated as
(TP+TN)/(TP+FN+TN+FP). Positive predictive value (PPV) was calculated as (TP)/(TP+FP) and
negative predictive value (NPV) was calculated as (TN)/(TN+FN).
This study was reviewed by Loma Linda University Institutional Review Board
(IRB). All research personnel completed the IRB certification and were trained in
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conducting phone interviews and data entry. Statistical analysis was performed using
SAS software, version 9.3.
Results
Table 4.1 shows the chi-square analysis between the entire CHF population and
the validated cases. The validated cases tended to be younger compared to the entire CHF
cohort (p value=0.02) and a lower proportion of the Black race/ethnicity was validated (p
value<0.01). Other validated case characteristics were representative of the entire CHF
cohort. Among the non-CHF population, there were no significant differences in
distribution of age, gender, education levels and other characteristic variables between
the validated sample population and the entire non-CHF cohort (Table 4.2).
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Table 4.1. CHF population: Baseline characteristic comparison between entire cohort
and validated cohort
Entire CHF
Validated cohort (%)
P value
cohort (%)
Gender
Women
609 (64.31)
54 (68.35)
0.47
Men
338 (35.69)
25 (31.65)
Age
<70
393 (41.46)
0.02
33 (41.77)
70-80
277 (29.22)
33 (41.77)
80+
278 (29.32)
13 (16.46)
Race/ethnicity
Black
216 (22.78)
7 (8.86)
<0.01
Non Black
732 (77.22)
72 (91.14)
Smoking history
Never smoker
Ever smoker
Years since diagnosis
<5 years ago
5-9 years ago
10+ years ago
BMI
Slim-normal (<24)
Overweight (25-29)
Obese (>30)
Education
High school or less
Some college
College grad or more
Comorbidity history
Type II Diabetes
Angina
Myocardial infarction
Hypertension
Hypercholesterolemia

Stroke
TIA
Cancer

635 (68.65)
290 (31.35)

58 (76.32)
18 (23.68)

0.16

522 (55.06)
215 (22.68)
211 (22.26)

42 (53.16)
24 (30.38)
13 (16.46)

0.22

305 (32.55)
264 (28.18)
368 (39.27)

22 (28.57)
27 (35.06)
28 (36.36)

0.43

325 (34.87)
405 (43.45)
202 (21.67)

21 (26.92)
39 (50.00)
18 (23.08)

0.35

341 (35.97)
224 (23.63)
290 (30.59)
707 (74.58)
505 (53.27)
95 (10.02)
156 (16.46)
260 (27.46)

29 (36.71)
18 (22.78)
24 (30.38)
51 (64.56)
48 (60.76)
6(7.59)
7(8.86)
22 (27.85)

0.90
0.87
0.97
0.05
0.20
0.49
0.08
0.94
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Table 4.1 (continued) CHF population: Baseline characteristic
entire cohort and validated cohort
Entire CHF
cohort (%)
Medication history
Aspirin
530 (56.75)
Cholesterol reducing med.
402 (42.45)
Antihypertensives
688 (72.73)

comparison between
Validated
cohort (%)

P value

44 (55.70)
42 (53.16)
51 (64.56)

0.86
0.06
0.12

Table 4.2. Non-CHF population: Baseline characteristic comparison between entire
cohort and validated cohort
Entire
Validated
P value
cohort (%)
cohort (%)
Gender
Women
41106 (64.17)
98 (66.67)
0.53
Men
22954 (35.83)
49 (33.33)
Age
<70
41906 (65.38)
102 (69.69)
0.21
70-80
14893 (23.24)
35 (23.81)
80+
7293 (1 1.38)
10(6.80)
Race/ethnicity
Black
14123 (22.04)
36 (24.49)
0.47
Non Black
49969 (77.96)
111 (75.51)
Smoking history
Never smoker
49823 (78.64)
117 (80.69)
0.61
Ever smoker
13294 (21.06)
28 (19.31)
BMI
Slim-normal (<24)
26731 (42.29)
50 (34.72)
0.18
Overweight (25-29)
55 (38.19)
21647 (34.15)
Obese (>30)
14830 (23.46)
39 (27.08)
Eudcation
High school or less
16276 (25.82)
0.52
41 (28.08)
Some college
24476 (38.84)
60 (41.10)
College grad or more
22273 (35.34)
45 (30.82)
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Table 4.2 (continued) Non-CHF population: Baseline characteristic comparison
between entire cohort and validated cohort
Entire
Validated
P value
cohort (%)
cohort (%)
Type II Diabetes
6792 (10.60)
14(9.52)
0.67
Angina
2048 (3.20)
4 (2.72)
0.74
Myocardial infarction
2322 (3.62)
0.89
5 (3.40)
Hypertension
22694 (35.41)
0.60
49 (33.33)
Hypercholesterolemia
20133 (31.41)
46 (31.29)
0.98
Stroke
894 (1.39)
2(1.36)
0.97
TIA
2156 (3.36)
5 (3.40)
0.98
Cancer
11767 (18.38)
0.29
22(14.97)
Medication history
Aspirin
18851 (29.66)
53 (36.3)
0.08
Cholesterol
10375 (16.21)
23 (15.65)
0.85

High blood pressure

19746 (30.90)

47 (31.97)

0.78

The validity of self-reported CHF was assessed using sensitivity, specificity and
predictive values. Sensitivity and NPV were excellent at 97.4% and 99.3%, respectively.
Specificity was 83.4% and PPV was 56.7%, with a total agreement of 86.0 % (Table
4.3). Nine cases and one non-case were unable to be validated due to incomplete medical
records.

Table 4.3 Validation Results
Diagnosis confirmed

Self- reported CHF

Yes
No

47

Yes

No

38
1

29
146

Discussion
The combination of the advanced age of the CHF population and the somewhat
confusing tenninology may make the validity of self-reported CHF challenging. There
are few validation studies on self-reported congestive heart failure. Our findings were
similar to other studies that involved CHF validation. The Olmsted Study validation
study was the only epidemiological study that involved a large study cohort, similar to
AHS-2. Among the total 2,037 self-reported cardiovascular diseases, the Olmsted Study
found a sensitivity of 68.6%, specificity of 97.0% for CHF. It had a high NPV and low
PPV at 36.8% and the accuracy was calculated at 96.3% for medical record-documented,
self-reported heart failure.3 The results indicated that self-reports of heart failure was
almost three-fold higher than confinned through medical records. The Medicare
Administrative and Health and Retirement Study (HRS) found that validation of heart
failure had lower sensitivity (25.2%) than the AHS-2 study, while the total agreement
was similar at 87.7%.4 The Cardiovascular Health Study (CHS), a cohort study of
coronary disease and stroke risk factors, found that self-reported CHF was confinned in
73.3% in men and 76.6% in women.5
Limitations
Difficulty in contacting subjects due to loss to follow-up or nonresponses could
have potentially biased the results. Of the selected cohort, cases were more challenging to
contact, possibly due to the older age distribution of the CHF population. Medical records
were received for approximately 38% of the cases while the response rate for non-cases
was almost 60%. Advanced ages of the cases is likely the primary reason for the lower
response rate. Older study participants are more likely to have transitioned from an
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independent living situation to assisted living facilities or nursing homes since the
completion of the baseline questionnaires or have since died, making the acquisition of
their medical records more difficult. The direction of the bias from non-responses is
difficult to predict.
Conclusion
Our findings demonstrate that there was representativeness between the entire
cohort and selected sample population among the cases and non-cases in age, gender.
education level and deceased status. We found that self-report of CHF correctly classified
in 85.6% of subjects as either cases or non-cases. Self-reported congestive heart failure
among the AHS-2 population may not be a reliable measure for future outcome research.
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CHAPTER 5

ADDITIONAL STUDIES

Association between Exercise and Risk of Cardiovascular Disease-Specific
Hospitalization among Heart Failure Patients in the Adventist Health Study 2

Of the 917 subjects who identified themselves as being diagnosed by a physician
with heart failure at enrollment into the AHS-2, 637 subjects returned a questionnaire on
hospitalizations two years later. Data on frequency, distance, duration and time spent
walking and running was collected at baseline and was combined into indices signifying
none, low and medium/high levels of exercise. Logistic regression was used to assess the
risk of cardiovascular-specific hospitalization according to baseline exercise levels and
other variables. Co-morbidities such as prevalent hypertension and type II diabetes were
analyzed as potential confounders, but were not found to have significant effect on the
outcome. Of several dietary factors tested, only meat intake made it into the final model.
In multivariate analysis, exercise was protective of cardiovascular-specific
hospitalization when compared to no exercise (OR=0.52, 95% Cl 0.32-0.96 and
OR=0.71, 95% Cl 0.42-1.81) for low and moderate/high levels, respectively.
Our findings suggest that exercise may be beneficial in preventing future heart
failure-related hospitalizations among heart failure patients. Higher frequency of exercise
may not be possible for many heart failure patients and may explain the point estimate we
obtained. The possibility that exercise level is actually a marker for disease severity and
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thus a better explanation of hospitalizations is a concern, but the variance in years living
with heart failure among the subjects did not significantly contribute to the outcome in
our analyses.
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Figure 5.1 Risk of CVD-related hospitalization by exercise level
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Table 5.1 Subject characteristics by hospitalization status

Gender
Male
Female
Age
Mean (in years)
Body Mass Index
(BMI)
Normal &
underweight
Overweight
Obese
Smoking status
No history
Past or current use
Education level
< High school
degree
< Associate's degree
College degree &
higher
Exercise level
None
Low
Medium/high
Type II diabetes
No history
History
Hypertension
Not present
Present
Meat Consumption
None
<lx/week
>2/week
Nut Consumption
<lx/week
>2/week

CVD
hospitalization (%)

Non-CVD or no
hospitalization (%)

Total (%)

82(12.9)
59 (9.3)

317(49.8)
178 (28.0)

399 (62.7)
237 (37.3)

72

73

46 (7.3)

167 (26.4)

213 (33.7)

33 (5.2)
60 (9.5)

152 (24.1)
174 (27.5)

185 (29.3)
234 (37.03)

91 (14.5)
47(7.5)

356 (56.8)
133 (21.2)

447 (71.3)
180 (28.7)

46(7.3)

154 (24.5)

200 (31.9)

59 (9.4)

208 (33.1)

267 (42.5)

34 (5.4)

127 (20.2)

161 (25.6)

71 (12.0)
22 (3.7)
35 (5.9)

206 (34.7)
114(19.2)
145 (24.5)

277 (46.7)
136 (22.9)
180 (30.4)

96(15.1)
45 (7.1)

344 (54.0)
152 (23.9)

440 (69.1)
197 (30.9)

40 (6.3)
101 (15.9)

170 (26.7)
326 (51.2)

210(40.0)
427 (67.0)

45 (7.3)
11 (1.8)
78 (12.7)

153 (24.9)
29 (4.7)
298 (48.5)

198 (32.3)
40 (6.5)
376 (61.2)

34(5.3)
107(16.8)

102 (16.0)
394 (61.9)

136(21.4)
501 (78.7)
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CHAPTER 6

A. Summary
This dissertation explored multiple aspects of populations with prevalent heart
failure. It consisted of investigating the relationship between drug therapy at
recommended dosages and the survival of inpatients with both systolic and diastolic heart
failure and it also evaluated the validity of self-reported congestive heart failure among
the Adventist Health Study-2 cohort.
The clinic study demonstrated that p-blocker, ACEi and ARB therapy at the target
dosages recommended by the Heart Failure Society of America improves survival among
patients with systolic heart failure and seems to do the same among subjects with
diastolic HF.
The validation study results show that the self-reported diagnosis of heart failure
in the AHS-2 population has high negative predictive value, but lower positive predictive
value. However, we were only able to contact a fraction of the subjects identified. The
study needs more intensive work in being able to reach a larger proportion of the subjects
in order to assess their status with respect to heart failure. Until a more complete follow
up has been done, it is unclear how useful self-report of CHF is as an outcome in the
AHS-2.
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B. Limitations
There are several limitations in the research work that must be addressed.
The major limitation with the study of the outpatient population at the
cardiomyopathy clinic was number of subjects and thus power. The main risk estimates
of survival did not reach statistical significance. The hazard ratios of [3-blocker and
ACEi/ARB dosages showed that survival of heart failure improved with recommended
dosages of medication, but was not statistically significant for either systolic or diastolic
hear failure.
The primary limitation of the Adventist Health Study-2 heart failure validation
study was non-responsiveness due to loss-to-follow-up. Both cases and non-cases were
attempted to be initially contacted by phone, but a significant portion of the phone
numbers were disconnected. Up-to-date phone numbers of participants with disconnected
numbers were sought by calling personal contacts and affiliate churches, and the
infonnation about these was obtained from the baseline questionnaire. Online people
searches were done after these sources had been exhausted. Despite these efforts, many
selected cases and non-cases were unable to be found. Tracking down the medical
records of deceased participants was even less successful due to the difficulty tracing
family members and close family friends who had knowledge of their fonner physicians.
In addition, the records of the deceased were often in remote storage or were otherwise
inaccessible.
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C. Conclusions
Results from the study conducted at Loma Linda University Medical Center
(LLUMC) cardiomyopathy clinic showed that recommended target dosages of Badrenergic blockade (p-blockers) and angiotensin-converting-enzyme inhibitors ACE
and/or angiotensin II receptor blockers (ARB) may reduce mortality among its systolic
heart failure patients. It also showed that p-blockers and ACEi/ARB therapy may
improve survival among diastolic heart failure patients. Improvements in heart failure
prognosis due to drug therapies seen in clinical trials translate to actual heart failure
prevalent populations such as the outpatients at LLUMC. These results may serve to give
assurance to medical practitioners that pushing for recommended dosages will be
worthwhile, whether their patients have systolic or diastolic heart failure.
The sensitivity, specificity and negative predictive values of self-reported
congestive heart failure were high in the Adventist Health Study-2 (AHS-2) heart failure
validation study. The total agreement between self-reported heart failure and medical
records was also good. Nearly 57% of self-reports of heart failure were validated by
medical records. Misperception of what heart failure is may have influenced the modest
positive predictive value.
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D. Recommendations
There is great potential, for both studies that make up this dissertation, for
continuation in the future.
It would be beneficial to gain more power in the clinic study from the Loma
Linda University Medical Center. Sufficient power can be achieved by an increase in
person-years. This can be done by either extending the enrollment period to include
more patients or by extending the length of the follow-up time of the study.
The Adventist Health Study-2 (AHS-2) self-reported heart failure study can be
continued in order to improve the response rate. More extensive people searches, using
online paid registries, can be done to minimize loss-to-follow-up. This will ensure that
the results are a well-rounded representation of the entire AHS-2 cohort.
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APPENDICES

A. Telephone script for CHF subjects

Good morning, my name is [name] and I am calling from the Adventist Health Study at
Loma Linda University. Is [name] available to answer some questions for the study?

Ifyes:
Hello, how are you doing today?
I am calling to confinn your responses to the questionnaire you completed when you
enrolled in the study several years ago.
You said that you had been diagnosed with heart failure. And we'd like to confirm your
diagnosis from your medical records. Would you give us pennission to obtain a copy of
your medical records to confinn your diagnosis?
Ifpennission is given:
Thank you very much. Be assured that we will protect the confidentiality of your records
just like any doctor's visit. We will need your signed pennission so I am going to send
you a standard consent fonn to sign and you should receive it in about a week. It just
needs your signature and then on the back you can fill out the contact infonnation of your
cardiologist. Do you have a cardiologist that you see regularly, a family doctor?
Once you sign the consent fonn and fill out the infonnation, you can send it right back to
us in the stamped envelope that will be included.
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Do you still live at [address]? Confirm address!
THANK YOU very much. We greatly appreciate your participation in AHS. We
encourage you to sign and send back the consent form as soon as you receive it in your
mail.
If no: Is there a better time to call back?
If deceased: Tm very sorry for your loss. When did he/she pass away?
The reason Tm calling is ...
[Name] in indicated that he/she had been diagnosed with heart failure in the questionnaire
when he/she first enrolled in the study. And we are trying to confirm his/her diagnosis
from medical records. Do you still have the contact information of the family doctor or
cardiologist that he/she saw regularly?
[Name of hospital/clinic, address, etc.] Again, THANK YOU very much. We greatly
appreciated [name]’s participation in AHS-2.
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B. Informed consent

The Adventist Health Study may be perfonned only by using personal information
relating to your health. National and international data protection regulations give you
the right to control the use of your medical infonuation. Therefore, by signing this form,
you specifically authorize your medical infonuation to be used or shared as described
below.

The following personal infonuation, considered “Protected Health Information” (PHI) is
needed to conduct this study and may include:

The date the congestive heart failure was diagnosed
Symptoms that prompted the diagnosis of the congestive heart failure
The ICD-10 code of the congestive heart failure
The level of disability after the event/ diagnosis and currently
The Imaging infonuation and findings
The reporting hospital/ clinic
The primary physician
The individual(s) listed at the top of this page will use this protected health infonuation
(PHI) to conduct the Adventist Health Study. It may on occasion during the course of the
study also be shared with the Institutional Review Board (IRB) and the Office of
Research Affairs of Loma Linda University.
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The main reason for sharing this infonnation is to be able to conduct the study as
described earlier in the consenting process. In addition, it is shared to ensure that the
study meets legal, institutional and accreditation standards.

All reasonable efforts will be used to protect the confidentiality of your PHI, which may
be shared with others to support this study, to carry out their responsibilities, to conduct
public health reporting and to comply with the law as applicable. Those who receive the
PHI may share with others if they are required by law.
Subject to any legal limitations, you have the right to access any protected health
information created during this study.

You may request this information from the

Principal Investigators named above,, but it will only become available after the study
analyses are complete. The authorization expires upon the conclusion of this research
study.

You may change your mind about this authorization at any time. If this happens, you
must withdraw your permission in writing. Beginning on the date you withdraw your
permission, no new personal health infonnation will be used for this study. However,
study personnel may continue to use the health infonnation that was provided before you
withdrew your pennission. If you sign this fonn and enter the study, but later change
your mind and withdraw your pennission, you will be removed from this part of the study
at that time. To withdraw your pennission, please contact the Principal Investigator or
study personnel at

1 -800-247-1699.
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You may refuse to sign this authorization. Refusing to sign will not affect the present or
future care you receive at this institution and will not cause any penalty or loss of benefits
to which you are entitled. However, if you do not sign this authorization form, you will
not be able to take part in this portion of the Adventist Health Study. You will receive a
copy of this signed and dated authorization.

I agree that my personal health information may be used for the study purposes described
in this form.
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C. Telephone script for non-CHF subjects

Good morning, my name is [name] and I am calling from the Adventist Health Study-2 at
Loma Linda University. Can I speak to [name]?

Ifyes:
Hello, I am calling today to confirm your responses to the questionnaire you completed
when you enrolled in the AHS in [date]. May I take a few moments of your time to
clarify some things with you?
a. Have you ever been told by a physician that you have congestive heart failure or
CHF? (If so, what date/year?)
b. Have you ever regularly experienced abnormal swelling in your lower extremities
within the last 5 years (If yes, did the doctor tell you the cause of this?)?
c. Have you ever regularly experienced abnormal shortness of breath with exertion or
when you're lying down within the last 5 years (If yes, did the doctor tell you the
cause of this?)?
d. Are you currently taking any heart medicines such as beta blockers, diuretics, ARB,
or ACE-inhibitor for (ankle) swelling or breathlessness? (Ask them to read list of
their medicines from bottles or a list, not off the top of their heads, exclude vitamins
or diet supplements)
e. Have you had an echo, or a heart ultrasound?
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Will ask for medical records if:
1.

subject answers yes to “a” OR

2. “b or “c” AND “d” or “e”

If their answers indicate that they have been diagnosed with CHF previous to enrollment
date:
Would you give us pennission to obtain a copy of your hospital records to confirm your
diagnosis?
If permission is given: Thank you very much. Be assured that we will protect the
confidentiality of your records just like any doctor’s visit. We will need your signed
pennission so I will send you a standard consent fonn to sign. You should receive it in
about a week. It will only need your signature and then you can send it right back to us in
the stamped envelope that will be included.
Do you have a family doctor or cardiologist that you see regularly? Can we have his
name and contact infonnation?
[Name, name of hospital/clinic, address]
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If their answers indicate that they have NOT been diagnosed with CHF: Go to end.

THANK YOU very much for your time. We greatly appreciate your participation in
AHS-2. We expect that this work will lead to new understanding about lifestyle and heart
disease and very much need you to continue on with the study.

If no: When would be a good time to call back? Thank you very much for your time.
If they cannot speakfor themselves or confused with questions: Ask if there is someone
there so can answer on their behalf (surrogate).

If they are next of kin: I am calling today to confinn Mr./Mrs. [name]’s responses to the
AHS-2 enrollment questionnaire that was filled out in [date] May I take a few moments
of your time to clarify some things with you? [Go to questions.]
If deceased: Tm very sorry for your loss.
Ask questions and ask for MD contact.
Conclusion
Again, THANK YOU very much. We greatly appreciate your participation in AHS-2.
We expect that this work will lead to new understanding about lifestyle and heart disease
and very much need you to continue on with the study.
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D. Letter to cardiologist / medical records

Dear Dr. [name],
Your patient [name] ([date of birth]) is a member of a lifestyle-disease outcome research
study called the Adventist Health Study (AHS-2), a longitudinal study of 96,000 subjects
from all over the United States. The health experience of subjects like your patient is
expected to be particularly informative in our research of how lifestyle factors may
prevent and modify diseases like heart failure.
Mr./Ms. [name] reported that he/she was diagnosed with heart failure previous to the
AHS-2 baseline questionnaire he/she completed in [date] and has signed the enclosed
consent form allowing us to contact you so that we can validate his/her diagnosis status at
study enrollment.
If your patient has NEVER been diagnosed with heart failure, we would appreciate it if
you check the box for the statement on the back of this page and mail it back to us. If
your patient has EVER been diagnosed with heart failure, we would appreciate if you
could fill out the short questionnaire on the back of this page and provide us with the
following information regarding the diagnosis and mail it back to us:
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1. Date of HF diagnosis
2. HF clinic notes near time of HF diagnosis
3. echo near time of HF diagnosis
4. ECG near time of HF diagnosis
5. BNP near time of HF diagnosis
6. Medication list near time of HF diagnosis
Although some of this information may not be available and your patient may have been
treated for HF prior to your first encounters, ANY details that you could supply would be
most helpful. Please contact the study at (800) 247-1699 if you have any questions.
Thank you for your attention and assistance in this matter.
/

Yours sincerely,

S''-"V

V

Gary E. Fraser MD, PhD, FRACP, FACC
Professor of Medicine, School of Medicine
Professor of Epidemiology, School of Public Health, Loma Linda University

E. Short questionnaire

1. Did your patient ever experience edema due to heart failure?
2. Did your patient ever experience dysnea due to heart failure?
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